Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Operating Expenses: 2020-2024

Historic Operating Expenses for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to $109.4 million.

  • Janux Therapeutics' Operating Expenses rose 24.72% to $45.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $154.3 million, marking a year-over-year increase of 55.83%. This contributed to the annual value of $109.4 million for FY2024, which is 35.00% up from last year.
  • Per Janux Therapeutics' latest filing, its Operating Expenses stood at $109.4 million for FY2024, which was up 35.00% from $81.1 million recorded in FY2023.
  • Janux Therapeutics' Operating Expenses' 5-year high stood at $109.4 million during FY2024, with a 5-year trough of $4.8 million in FY2020.
  • Its 3-year average for Operating Expenses is $88.7 million, with a median of $81.1 million in 2023.
  • Data for Janux Therapeutics' Operating Expenses shows a peak YoY soared of 655.03% (in 2021) over the last 5 years.
  • Yearly analysis of 5 years shows Janux Therapeutics' Operating Expenses stood at $4.8 million in 2020, then skyrocketed by 655.03% to $36.6 million in 2021, then spiked by 107.03% to $75.7 million in 2022, then grew by 7.08% to $81.1 million in 2023, then skyrocketed by 35.00% to $109.4 million in 2024.